Recursion Pharmaceuticals, Inc (RXRX) insider trading
Every open-market stock purchase and sale by Recursion Pharmaceuticals, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Blake Borgeson (Director) and 2 others sold $644K in the last 90 days.
- Last insider buy: Mubadala Investment Co PJSC (10% owner), $522K, 3 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $8.2M (36 sales). Last close $3.64 on Oct 21, 2026.
Recent RXRX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Oct 6, 2026 | Blake Borgeson (Director) | Sold | $242K |
| Oct 6, 2026 | Robert Hershberg (Director) | Sold | $125K |
| Oct 6, 2026 | Robert Hershberg (Director) | Bought (not open market) | $55.5K |
| Oct 1, 2026 | Dean Y Li (Director) | Bought (not open market) | — |
| Oct 1, 2026 | Zavain Dar (Director) | Bought (not open market) | — |
| Sep 15, 2026 | Ben R Taylor (CFO) | Sold (not open market) | $18.4K |
| Sep 8, 2026 | Najat Khan (CEO) | Sold | $78.8K |
| Sep 1, 2026 | Blake Borgeson (Director) | Sold | $100K |
| Aug 17, 2026 | Najat Khan (CEO) | Sold (not open market) | $254K |
| Aug 17, 2026 | David Hallett (C-suite exec) | Sold (not open market) | $84.2K |
| Aug 17, 2026 | Ben R Taylor (CFO) | Sold (not open market) | $79.1K |
| Aug 4, 2026 | Blake Borgeson (Director) | Sold | $97.5K |
| Jul 7, 2026 | Blake Borgeson (Director) | Sold | $159K |
| Jul 1, 2026 | Zavain Dar (Director) | Bought (not open market) | — |
| Jul 1, 2026 | Dean Y Li (Director) | Bought (not open market) | — |
| Jun 18, 2026 | Namandje Bumpus (Director) | Sold | $12.6K |
| Jun 17, 2026 | Zavain Dar (Director) | Bought (not open market) | — |
| Jun 17, 2026 | Namandje Bumpus (Director) | Bought (not open market) | — |
| Jun 17, 2026 | Robert Hershberg (Director) | Bought (not open market) | — |
| Jun 17, 2026 | Dean Y Li (Director) | Bought (not open market) | — |
| Jun 17, 2026 | Franziska Michor (Director) | Bought (not open market) | — |
| Jun 17, 2026 | Elaine D Sun (Director) | Bought (not open market) | — |
| Jun 17, 2026 | Blake Borgeson (Director) | Bought (not open market) | — |
| Jun 15, 2026 | Ben R Taylor (CFO) | Sold (not open market) | $17K |
| Jun 5, 2026 | Christopher Gibson (Director) | Sold | $145K |
Who's trading RXRX
- Robert Hershberg, Director: sold $125K (1 sale), last Oct 6, 2026
- Blake Borgeson, Director: sold $4.3M (11 sales), last Oct 6, 2026
- Dean Y Li, Director: other filings, last Oct 1, 2026
- Zavain Dar, Director: other filings, last Oct 1, 2026
- Ben R Taylor, CFO: sold $158K (3 sales), last Sep 15, 2026
- Najat Khan, Officer: sold $807K (4 sales), last Sep 8, 2026
- David Hallett, C-suite exec: other filings, last Aug 17, 2026
- Namandje Bumpus, Director: sold $28.1K (2 sales), last Jun 18, 2026
- Elaine D Sun, Director: other filings, last Jun 17, 2026
- Franziska Michor, Director: other filings, last Jun 17, 2026
- Christopher Gibson, CEO: sold $2.8M (15 sales), last Jun 5, 2026
Get free alerts when an insider at Recursion Pharmaceuticals, Inc files a new trade →